February 26th - Antibody Therapeutics Xchange 2024 in San Diego

The Antibody Therapeutics Xchange 2024, set to take place in San Diego on February 26th, is a highly anticipated event in the world of antibody therapeutics, and Biointron is proud to be a part of it. Organized by hubXchange, this conference is designed as a unique platform for executives from the pharmaceutical and biotech industries to engage in in-depth discussions and collaborations on the development of antibody therapeutics.

This year's event is structured around interactive roundtable discussions. The discussions will cover a wide range of topics, including Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics, and the use of Emerging Technologies in the field. These sessions are facilitated by industry experts, ensuring that each conversation is rich in content and insights. Speakers across the antibody industry will also share their expertise, offering a comprehensive view of the latest trends and challenges in the industry.

The Antibody Therapeutics Xchange 2024 is more than just a series of discussions; it's a hub for networking and collaboration. The event includes multiple networking breaks, lunches, and a special drinks-canapé reception, providing an excellent opportunity for attendees;to connect with industry leaders and peers in a relaxed setting. Moreover, the choice of the Handlery Hotel San Diego as the venue further enhances the experience, offering a comfortable and convenient location for this gathering of minds.

Biointron is excited to participate in this conference and invites everyone interested in the field of antibody therapeutics to join us. The event promises to be an invaluable opportunity for professionals to gain insights, share knowledge, and engage with other industry experts. It's an ideal platform for both seasoned professionals and newcomers to the field, offering a wealth of experiences and learning opportunities. We look forward to meeting you there and contributing to the advancement of antibody therapeutics together.